In addition, pemetrexed led to increased release of pro-inflammatory cytokines (e.g., IFN-γ and IL-2), that further stimulated PD-L1 expression on tumor cells, resulting in an immune favorable TME for anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and neoplasm.